Researching: Pfizer

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation

Race intensifies to lead next wave of obesity drugs as trial results loom

AstraZeneca’s Imfinzi Gains Ground in Bladder Cancer as Volga Trial Delivers

BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial

FDA hands Pfizer, Arvinas’ Veppanu early approval for breast cancer subtype

Arvinas’ ‘Protac’ breast cancer drug cleared by FDA

Pfizer deals extend patent life for a top-selling rare disease drug

Pfizer settles with 2 generic Vyndamax makers in latest twist to ATTR market: analysts

Regeneron Seals Final 'Most Favored Nation' Drug Pricing Pact with White House

Lilly Bets $3.25B on Kelonia to Push In‑Vivo CAR‑T from Concept to Platform